Drug intelligence / Profile preview

ALY-201

Development stage: Unknown
Lead developer: Alys Pharmaceuticals
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

ALY-201 is a topical gel drug candidate under development by Alys Pharmaceuticals for the treatment of radio-induced dermatitis (radiodermatitis). It is being developed specifically for skin-related therapeutic areas and is currently in Phase 1 clinical trials. The drug is administered via the topical route as a gel formulation. Its precise mechanism of action has not been disclosed in public sources, but it targets dermatological conditions associated with radiation exposure[1][2].

Beyond the preview

Go deeper on ALY-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALY-201.

Explore the full profile